Evidence map›Paper›PMID 41276555›Full record

Observational studyScientific reports2025

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters.

Mouna Ballan-Haj, Kareem Midlej, Barbara Silverman, Regina Draliuk, Elena Mishchenko, Olga Valkovsky, Shoshan Perek, Amir Warwar, Ibraheem Zoabi, Meir Preis

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mouna Ballan-Haj *Institute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Kareem Midlej *Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Barbara SilvermanFaculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Regina DraliukInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Elena MishchenkoInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Olga ValkovskyInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Shoshan PerekInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Amir WarwarInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Ibraheem ZoabiInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel.
Meir PreisInstitute of hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel. Meirpr@clalit.org.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple Myeloma (MM) is characterized by multifaceted symptoms stemming from the disease itself, treatment complications, and involvement of various organs. MM significantly impacts the lives of patients and caregivers. This study aims to assess Patient Reported Outcome Measures (PROMs) and Family Reported Outcome Measures (FROMs) alongside conventional evaluation tools. A quantitative, prospective, observational study was conducted involving active MM patients. Participants completed PROMs/FROM-16 questionnaires quarterly for 12 months. Spearman correlation analysis was employed to explore associations between PROMs/FROM-16 and disease evaluation parameters. Friedman's test and Wilcoxon's test compared mean PROMs/FROM-16 scores at study onset with the following months. A better disease evaluation correlated with improvements in reported disease symptoms or treatment side effects by patients and with a reduced burden reported by caregivers (FROM-16). Additionally, favorable results in calcium levels, renal insufficiency, anemia, and bone lesions (CRAB) were associated with higher PROMs scores and less impact on caregivers. Moreover, patient PROMs scores reflected caregiver challenges and their ability to cope with the patient's illness. Most of the domains in PROMs demonstrated improvement, especially- quality of life, disease symptoms, body image scale, and future perspective, which improved 6 points that were defined in previous studies as minimal important difference. Finally, the results of our study showed that the total FROM-16 score improved from a mean score of 14.95 to 10.86 between the third month of the study, compared to the sixth month of the study, i.e., higher than 4, the minimal important change as defined in a previous study. This study underscores the utility of PROMs/FROM-16 in evaluating patient status from their perspective, facilitating tailored treatment approaches. It emphasizes the necessity of further research into the caregiver's experience with MM.

Indexed as

Multiple MyelomaPatient Reported Outcome MeasuresAdultAgedAged, 80 and overCaregiversFamilyFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeSurveys and QuestionnairesDisease evaluationFROM-16Multiple myelomaPROMsQuality-of-life

Identifiers

PMID41276555
PMCPMC12748695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.